Epilepsy is a neurological disorder affecting around 1%–2% of population worldwide and its
treatment includes use of antiepileptic drugs to control seizures. Failure to respond to …

Glutathione (GSH) depletion, and impaired redox homeostasis have been observed in
experimental animal models and patients with epilepsy. Pleiotropic strategies that elevate …

Background Epilepsy is a prevalent neurological disease, affecting approximately 1–2% of
the global population. The hallmark of epilepsy is the occurrence of epileptic seizures, which …

N-acetylcysteine (NAC) is an antioxidant with some demonstrated efficacy in a range of
neuropsychiatric disorders. NAC has shown anticonvulsant effects in animal models. NAC …

Background: Homocysteine and taurine are non-proteinogenic sulfur-containing amino
acids with numerous important physiological roles. Homocysteine and taurine are …

Memory impairment is a critical issue in patients with temporal lobe epilepsy (TLE).
Neuronal loss within the hippocampus and recurrent seizures may cause cognitive …

Abstract Introduction/Aim Epilepsy is widely investigated as a common neurological disease
requiring pharmacologically effective agents. N-acetyl cysteine (NAC), has become a …

Understanding the underlying molecular mechanisms involved in epilepsy is critical for the
development of more effective therapies. It is believed that mTOR (Mechanistic Target of …

The Wistar Audiogenic Rat (WAR) strain is a genetic model of epilepsy, specifically
brainstem-dependent tonic-clonic seizures, triggered by acute auditory stimulation. Chronic …

The glutathione precursor N-acetyl-l-cysteine (NAC) is currently being tested on Parkinson's
patients for its neuroprotective properties. Our studies have shown that NAC can elicit …